Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2024 Rev YoY: -6.9% EPS YoY: -1,845.8% Move: +4.60%

AngioDynamics Inc

ANGO

$11.37 4.60%

Exchange NASDAQ Sector Healthcare Industry Medical Instruments Supplies

Q3 2024

Published: Apr 9, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for ANGO

Reported

Report Date

Apr 9, 2024

Quarter Q3 2024

Revenue

75.18M

YoY: -6.9%

EPS

-4.67

YoY: -1,845.8%

Market Move

+4.60%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $75.18M down 6.9% year-over-year
EPS of $-4.67 decreased by 1% from previous year
Gross margin of 43.3%
Net income of -187.74M
""This approval [for AlphaVac] opened up another large, fast-growing market for us, and we are excited to put AlphaVac in more physiciansâ€™ hands."" - Jim Clemmer

ANGO

AngioDynamics Inc

Period Q3 2024

Currency USD

Report Type Quarterly Earnings

Generated Apr 1, 2026

Swipe to view all report sections

Executive Summary

In Q3 2024, AngioDynamics Inc (ANGO) reported a revenue of $66 million, a year-over-year increase of 8%, driven primarily by its Med Tech segment, which grew nearly 13%. The company made significant strategic strides, including the successful clearance from the FDA for AlphaVac to treat pulmonary embolism. This expanded indication positions AngioDynamics to capitalize on a fast-growing market segment, demonstrating the effectiveness of its focused product development strategy. Despite a challenging financial quarter highlighted by a GAAP net loss of $190.4 million, management asserts their commitment to optimizing the product portfolio and transitioning to an outsourced manufacturing model, which is expected to enhance operational margins in the longer term.

Key Performance Indicators

Revenue

Decreasing

75.18M

QoQ: -4.92% | YoY: -6.85%

Gross Profit

Decreasing

32.57M

43.33% margin

QoQ: -19.09% | YoY: -19.58%

Operating Income

Decreasing

-11.60M

QoQ: 11.60% | YoY: -117.52%

Net Income

Decreasing

-187.74M

QoQ: -546.30% | YoY: -1 879.29%

EPS

Decreasing

-4.67

QoQ: -548.61% | YoY: -1 845.83%

Revenue Trend

Margin Analysis

Financial Highlights

Financial Performance Overview
- Revenue: $66 million (up 8% YoY)
- Gross Profit: $32.57 million, showing a decline in gross profit margin to 51.1% from 53.3% YoY.
- Operating Income: -$11.6 million, reflecting operational challenges including increased costs in transitioning to outsourced manufacturing.
- Net Income: -$190.4 million, heavily influenced by goodwill impairment and settlement expenses totaling $190.3 million.
- EPS: -$4.73, indicating significant loss per share compared to previous periods.

Balance Sheet Highlights
- Total Assets: $324.84 million
- Total Liabilities: $106.14 million
- Cash and Cash Equivalents: $78.45 million, reflecting a healthy liquidity position post-divestitures, with zero debt compared to $50 million a year ago.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	75.18M	-6.85%	-4.92%
Gross Profit	32.57M	-19.58%	-19.09%
Operating Income	-11.60M	-117.52%	11.60%
Net Income	-187.74M	-1 879.29%	-546.30%
EPS	-4.67	-1 845.83%	-548.61%

Key Financial Ratios

Gross Profit Margin

Good

43.30%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Weak

-0.15%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-2.50%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.58%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.86%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

2.29

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Conservative

0.02

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-0.29x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.01x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2026	79.43	-0.15	+17.7%	View
Q1 2026	75.71	-0.26	+6.7%	View
Q3 2025	72.00	-0.11	-4.2%	View
Q2 2025	72.85	-0.26	-7.9%	View
Q1 2025	67.49	-0.31	-14.2%	View
Q3 2024	75.18	-4.67	-6.9%	View

ANGO

AngioDynamics Inc

Q2 2026 Report

AngioDynamics Inc (ANGO) QQ2 2026 Results: Med Tech-led Growth, Margin Expansion, and Raised Full-Year Guidance...

Read full report

ANGO

AngioDynamics Inc

Q1 2026 Report

AngioDynamics Inc (ANGO) QQ1 2026 Results Analysis: Revenue Growth Amid Margin Pressure and Cash Flow Challenges...

Read full report

ANGO

AngioDynamics Inc

Q3 2025 Report

AngioDynamics Inc (ANGO) Third Quarter Financial Results 2025: Strong Growth in MedTech Segment...

Read full report

ANGO

AngioDynamics Inc

Q2 2025 Report

AngioDynamics Inc (ANGO) Q2 2025 Financial Results: Strong Growth in MedTech Drives Recovery...

AngioDynamics Inc (ANGO) Q3 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More ANGO Quarterly Reports

ANGO

ANGO

ANGO

ANGO

ANGO

Q3 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

ANGO Full Profile

ANGO Financial Statements

Earnings Calendar